Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
29. Februar 2024 16:40 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18. Januar 2024 12:00 ET
|
Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
06. Dezember 2023 07:00 ET
|
Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis ...
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
22. November 2023 09:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
09. November 2023 07:00 ET
|
Optinose, Inc.
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D...
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
27. Oktober 2023 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the 2023 Cantor Global Healthcare Conference
22. September 2023 09:01 ET
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
10. August 2023 07:00 ET
|
Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
27. Juli 2023 07:00 ET
|
Optinose, Inc.
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 ...
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
16. Juni 2023 16:08 ET
|
Optinose, Inc.
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...